Lil­ly ax­es PhI­II tri­al of Verzenio in prostate can­cer

Eli Lil­ly culled a Phase III tri­al test­ing its can­cer drug Verzenio in pa­tients with cas­tra­tion-re­sis­tant prostate can­cer af­ter it failed to im­prove pro­gres­sion-free sur­vival …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER